[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"normal-weight\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:normal-weight":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100573952","hormonal-control-of-energy-and-macronutrient-intake-in-obesity-memory-100573952",false,"NCT06752967","Hormonal Control of Energy and Macronutrient Intake in Obesity (MEMORY)","Hormonal Control of Energy and Macronutrient Intake in Obesity","MEMORY","Inclusion Criteria:\n\n* Age 18-45 years\n* For women: Regular menstruation\n* BMI-range 18.5-39.9 kg\u002Fm\\^2\n\nExclusion Criteria:\n\n* Not able or willing to eat or drink the test meals because of e.g., allergy or intolerance\n* Daily smoking\n* For women: Pregnancy \u002F planned pregnancy (within the study period) \u002F lactating\n* Self-reported history of an eating disorder\n* Self-reported weight change (kg) within two months prior to inclusion\n* HbA1c ≥48 mmol\u002Fmol\n* Treatment with antidepressants\n* Alcohol\u002Fdrug abuse or in treatment with disulfiram (antabus) at time of inclusion\n* Uncontrolled medical issues including but not limited to cardiovascular pulmonary, rheumatologic, hematologic, oncologic, infectious, gastrointestinal, or psychiatric disease; diabetes or other endocrine disease; immunosuppression\n* Current treatment with medication which significantly affect appetite or energy balance (e.g., GLP-1 receptor agonists)\n* Bariatric surgery\n* Unable to understand the informed consent and the study procedures\n* Concomitant participation in intervention studies\n* Participant's withdrawal of the informed consent\n* Other safety concerns - judged by the investigator",true,"ALL","18 Years","45 Years",{"count":22,"type":23},45,"ESTIMATED","INTERVENTIONAL",[26],"NA","The overall aim of the MEMORY study is to examine the concept of 'food memory' - how specific macronutrient compositions influence subsequent food preference and intake, and whether this differs across the BMI range from normal weight to obesity.",[29,30,31],"Obesity","Normal Weight","Overweight",[33,34,35,36,37,38,39],"ad libitum buffet","Food preferences","Macronutrient","Appetite","Appetite hormones","FGF21","Glucagon","RECRUITING","2026-04-23",{"date":43,"type":44},"2026-04-24","ACTUAL",{"date":46,"type":44},"2024-12-12",{"date":48,"type":23},"2026-06-29",{"name":50,"class":51},"Steno Diabetes Center Copenhagen","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":24,"phases":63,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":52},"100553572","effect-of-glp1-receptor-agonist-on-brain-insulin-responsiveness-100553572","NCT06487832","Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness","Impact of the Incretin System on Brain Insulin Sensitivity in Humans with Normal Weight, Overweight and Obesity","Inclusion Criteria:\n\n* BMI between 18.5 and 24.9 kg\u002Fm2; and between 27.5 kg\u002Fm2 and 40 kg\u002Fm2\n* Written consent to participate in the study\n* Written consent to be informed about incidental findings\n\nExclusion Criteria:\n\n* Type 1 or type 2 diabetes, LADA, MODY, or cardiovascular diseases such as chronic heart failure, myocardial infarction, status post stroke\n* BMI \\\u003C 18.5 or \\> 40 kg\u002Fm2\n* Persons who cannot legally give consent\n* Pregnancy or lactation\n* History of severe mental or somatic disorders including neurological diseases (incl. epileptic seizures)\n* Taking psychotropic drugs\n* Chronic diseases or medication that influence glucose metabolism\n* Regular use of analgesic drugs\n* Previous bariatric surgery\n* Known allergy against one or more of the used agents\n* Acute infection and\u002For antibiotic treatment within the last 4 weeks\n* Hemoglobin values less than 10.5 g\u002Fdl for women, less than 11.5 g\u002Fdl for men\n* Other diseases that in the opinion of the investigator may jeopardize the success of the study or indicate a risk to the volunteer\n* Participation in a lifestyle intervention study or a pharmaceutical study within the last 30 days\n* Metal implants which cannot be removed as pacemakers, artificial heart valve, electrical devices as insulin pumps, large tattoos, retainer over more than 4 teeth, contraceptive coil, implanted magnetic metal parts as screws or plates after a surgery\n* Persons with claustrophobia\n* Persons with tinnitus\n* Weight loss or gain of \\>5% in the last 3 months\n* Pancreatic diseases\n* History or family history of multiple endocrine neoplasia (MEN2) or medullary thyroid cancer\n* History of malignant thyroid disease\n* History of malignant disease in the past 5 years\n* Surgery in the last three months\n* Chronic tobacco use of more than 10 cigarettes\u002Fday\n* Women who do not consent to refrain from breastfeeding until 2 months after the end of the study\n* Women of childbearing age who do not consent to use safe method of contraception from 28 days before until 2 months after the end of the study or refrain from heterosexual intercourse during this time\n* Women of childbearing age who do not consent to take a pregnancy test","70 Years",{"count":62,"type":23},60,[26],"The overarching goal of the current study is to investigate the effect of GLP-1 on brain insulin responsiveness in a randomized, single-blinded, within subject cross-over study design. To this end, investigators will compare the effect of the administration of semaglutide versus placebo, followed by an fMRI with administration of intranasal insulin or placebo.",[30,66,67,68],"Overweight and Obesity","Insulin Sensitivity","Insulin Resistance",[70,71,72,73],"GLP-1","Brain","functional magnetic resonance imaging","Semaglutide","2025-03-25",{"date":76,"type":44},"2025-03-30",{"date":78,"type":44},"2024-07-01",{"date":80,"type":23},"2027-12-31",{"name":82,"class":51},"University Hospital Tuebingen"]